Ricky Goldwasser
Stock Analyst at Morgan Stanley
(3.36)
# 994
Out of 5,055 analysts
229
Total ratings
63.92%
Success rate
9.38%
Average return
Main Sectors:
Stocks Rated by Ricky Goldwasser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $170 → $185 | $167.81 | +10.24% | 23 | Nov 11, 2025 | |
| CNC Centene | Maintains: Equal-Weight | $28 → $38 | $36.38 | +4.45% | 14 | Oct 14, 2025 | |
| UNH UnitedHealth Group | Maintains: Overweight | $325 → $395 | $321.86 | +22.72% | 20 | Sep 12, 2025 | |
| LH Labcorp Holdings | Maintains: Overweight | $283 → $306 | $266.89 | +14.65% | 17 | Jul 25, 2025 | |
| DOCS Doximity | Maintains: Equal-Weight | $71 → $60 | $49.62 | +20.92% | 10 | Apr 24, 2025 | |
| LFST LifeStance Health Group | Reiterates: Overweight | $10 | $6.40 | +56.25% | 8 | Apr 22, 2024 | |
| GDRX GoodRx Holdings | Maintains: Equal-Weight | $8 → $5.5 | $2.97 | +85.19% | 9 | Nov 10, 2023 | |
| OSCR Oscar Health | Maintains: Equal-Weight | $5 → $7.5 | $13.88 | -45.97% | 6 | Aug 30, 2023 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $19 → $12 | $16.52 | -27.36% | 8 | Aug 30, 2023 | |
| DGX Quest Diagnostics | Reiterates: Equal-Weight | $145 | $186.95 | -22.44% | 17 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $365 | $137.54 | +165.38% | 7 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $403 → $420 | $842.09 | -50.12% | 27 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $120 | $4.05 | +2,862.96% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $549 → $620 | $237.12 | +161.47% | 11 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $485 → $500 | $325.83 | +53.45% | 2 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $124 | $77.81 | +59.36% | 9 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $296 → $318 | $269.66 | +17.93% | 11 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $70 | $205.37 | -65.92% | 17 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $182 → $195 | $220.61 | -11.61% | 6 | Oct 21, 2020 |
Charles River Laboratories International
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $170 → $185
Current: $167.81
Upside: +10.24%
Centene
Oct 14, 2025
Maintains: Equal-Weight
Price Target: $28 → $38
Current: $36.38
Upside: +4.45%
UnitedHealth Group
Sep 12, 2025
Maintains: Overweight
Price Target: $325 → $395
Current: $321.86
Upside: +22.72%
Labcorp Holdings
Jul 25, 2025
Maintains: Overweight
Price Target: $283 → $306
Current: $266.89
Upside: +14.65%
Doximity
Apr 24, 2025
Maintains: Equal-Weight
Price Target: $71 → $60
Current: $49.62
Upside: +20.92%
LifeStance Health Group
Apr 22, 2024
Reiterates: Overweight
Price Target: $10
Current: $6.40
Upside: +56.25%
GoodRx Holdings
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $8 → $5.5
Current: $2.97
Upside: +85.19%
Oscar Health
Aug 30, 2023
Maintains: Equal-Weight
Price Target: $5 → $7.5
Current: $13.88
Upside: -45.97%
Alignment Healthcare
Aug 30, 2023
Maintains: Overweight
Price Target: $19 → $12
Current: $16.52
Upside: -27.36%
Quest Diagnostics
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $145
Current: $186.95
Upside: -22.44%
Jul 14, 2023
Reiterates: Overweight
Price Target: $365
Current: $137.54
Upside: +165.38%
Jan 6, 2023
Maintains: Overweight
Price Target: $403 → $420
Current: $842.09
Upside: -50.12%
Jan 6, 2023
Maintains: Overweight
Price Target: $140 → $120
Current: $4.05
Upside: +2,862.96%
Oct 31, 2022
Maintains: Overweight
Price Target: $549 → $620
Current: $237.12
Upside: +161.47%
Oct 21, 2022
Maintains: Equal-Weight
Price Target: $485 → $500
Current: $325.83
Upside: +53.45%
Oct 11, 2022
Maintains: Overweight
Price Target: $127 → $124
Current: $77.81
Upside: +59.36%
Aug 17, 2022
Maintains: Overweight
Price Target: $296 → $318
Current: $269.66
Upside: +17.93%
Jul 14, 2022
Maintains: Overweight
Price Target: $74 → $70
Current: $205.37
Upside: -65.92%
Oct 21, 2020
Maintains: Overweight
Price Target: $182 → $195
Current: $220.61
Upside: -11.61%